Navigation Links
Research Demonstrates Possible Texas Job Losses from Sectors Supported by Biopharmaceutical Companies
Date:9/27/2011

WASHINGTON, Sept.  27, 2011 /PRNewswire-USNewswire/ -- Thousands of jobs in Texas supported by the biopharmaceutical research sector would be threatened if harmful policies – such as imposing new taxes in the Medicare prescription drug program – were enacted by federal policymakers.

From research to technical work, manufacturing to construction and other building services, equipment suppliers to child care services, the biopharmaceutical sector supports a broad array of high-quality jobs.

A report by the Battelle Technology Partnership Practice shows that reducing the biopharmaceutical sector's annual revenue by $20 billion would be a serious blow to employment in key regions throughout the country, including Texas, where over 6,000 jobs would be permanently lost. Overall, the impact would be a potential permanent loss of 260,000 jobs nationwide.  

While the Battelle research is not specific to any one policy or event, proposals being considered, such as government-mandated price controls in Part D, would be expected to have an annual revenue impact of this magnitude.

The President and some in Congress have proposed government-mandated price controls in Medicare Part D as part of ongoing budget discussions. Such a policy would have a dramatic negative effect on Texas' economy and patients, and could undermine the success of the Part D program.

"Biopharmaceutical companies produce the highest-value jobs – the kinds of jobs that can drive future economic growth in Texas. At a time when the U.S. is facing a jobs crisis, as evidenced by Texas' 8.5 percent unemployment rate, it is critical that our policymakers embrace dynamic and innovative business sectors such as the biopharmaceutical industry and refrain from stifling job growth through shortsighted proposals," said Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani.

Beyond jobs, over $40 million in state and local taxes would be jeopardized – including over $5 million generated directly by the biopharmaceutical sector, the report shows. In addition, Texas would lose over $1.5 billion in total economic output.

Equally important to protecting jobs is protecting the health of Texas' seniors. Medicare Part D has been an unparalleled success, providing seniors with access to life-saving medicines, generating high satisfaction rates and costing far less than original government projections. Over 55 percent of Texas' Medicare beneficiaries are enrolled in a Part D plan, according to the Centers for Medicare and Medicaid Services.

"Policies that discourage R&D and cutting-edge science – inevitably slowing the development of needed future medicines – are not fair to seniors waiting for new treatments against our most challenging and costly diseases," Castellani said.

"Our economy is at a critical juncture. We have to create jobs, not lose more. We have to support innovation, not interfere with the most innovative sectors of our economy. We must continue to improve the health of America's seniors, not increase costs and erect barriers to promising scientific breakthroughs," he added.

The research, supported by PhRMA, is available on our website at: http://www.phrma.org/sites/default/files/84/battelle-phrmabiopharmaceuticalsimpacts-usandstatesummary.pdf

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $49.4 billion in 2010 in discovering and developing new medicines. Industry-wide research and investment reached a record $67.4 billion in 2010. 

Find PhRMA Online:


For information on how innovative medicines save lives, visit: http://www.innovation.org.

For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org.

For information on ensuring the flow of medicines during public health emergencies, visit http://www.rxresponse.org.


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016 Augmedix, the nation,s leading smartglass-based ... closed a $23 million strategic round of funding ... company seeks to rehumanize the physician patient relationship ... EHR documentation. The Augmedix core offering is a ... from 3 hours of mandated charting and documentation ...
(Date:12/8/2016)... N.Y. , Dec. 8, 2016 Henry Schein, ... of health care products and services to office-based dental, animal ... 80 percent equity investment in Marrodent, one of ... of approximately $32 million. This transaction was announced on August ... customers in Poland since 2014, and ...
(Date:12/8/2016)... , and SAN DIEGO , Dec. ... services and solutions with cutting edge next-generation sequencing and bioinformatics ... biotechnology company; and the Genome Institute of Singapore ... – a new joint venture between Novogene and AITbiotech – ... Biopolis, Singapore .   The ...
Breaking Medicine Technology:
(Date:12/8/2016)... , ... December 08, 2016 , ... California Senate Bill ... payments per workers’ compensation claim in 2013 and 2014, according to CompScope™ Medical ... Institute (WCRI) . , According to the study, medical payments per claim in California ...
(Date:12/8/2016)... ... December 08, 2016 , ... Vida Health, the digital ... B led by Canvas Ventures . Other investors include Nokia Growth Partners (NGP) ... platform to serve more consumers who are managing chronic conditions or simply ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... financial planning services from offices headquartered in Jefferson County, is announcing the launch ... Shelter in Birmingham. , The number of homeless women and children in Birmingham ...
(Date:12/8/2016)... Bay St. Louis, MS (PRWEB) , ... December 08, 2016 , ... ... with offices that serve commercial and residential clients in and around the Hancock County ... community support for the Hancock County Food Pantry. , The Hancock County Food Pantry ...
(Date:12/7/2016)... KING OF PRUSSIA, PA (PRWEB) , ... December 07, 2016 , ... ... of clinical trials with the announcement that it is one of the early adopters ... EU-U.S. Privacy Shield Framework is designed to provide companies on both sides of the ...
Breaking Medicine News(10 mins):